Evidence map›Paper›PMID 26082912›Full record

ArticleEuropean journal of neurodegenerative disease2012

Interleukin-1β in Central Nervous System Injury and Repair.

Sandra J Hewett, Nicole A Jackman, Robert J Claycomb

Abstract read
In one paragraph

Article in European journal of neurodegenerative disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Astrocytes in aging.Neuron · 2025
    Review

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sandra J HewettDepartment of Biology, Program In Neuroscience, Syracuse University, Syracuse, NY 13244.
Nicole A Jackman *Department of Neuroscience, University of Connecticut Health Center, Farmington, CT 06030.
Robert J Claycomb *Department of Neurology, Yale University, New Haven, CT 06511.

Funding

IL-1 in Protection and InjuryR01NS051445 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HEWETT, SANDRA J · 2006 to 2017
$3.2M
Neuroscience Training at University of Connecticut Health CenterT32NS041224 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI EIPPER, ELIZABETH ANNE · 2001 to 2010
$1.3M
Regulation of System xc- by Interleukin-1 betaR36AG035036 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI JACKMAN, NICOLE ALYSE · 2009 to 2010
$110k
Regulation of System xc- by Interleukin-1BetaF31NS066745 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI JACKMAN, NICOLE ALYSE · 2009 to 2009
$31k
NIA NIH HHS R36 AG035036NINDS NIH HHS F31 NS066745NINDS NIH HHS R01 NS051445NINDS NIH HHS T32 NS041224
6 · The paper itself

Abstract

Acute inflammation is a self-limiting, complex biological response mounted to combat pathogen invasion, to protect against tissue damage, and to promote tissue repair should it occur. However, unabated inflammation can be deleterious and contribute to injury and pathology. Interleukin-1β (IL-1β), a prototypical "pro-inflammatory" cytokine, is essential to cellular defense and tissue repair in nearly all tissues. With respect to brain, however, studies suggest that IL-1β has pleiotrophic effects. It acts as a neuromodulator in the healthy central nervous system (CNS), has been implicated in the pathogenic processes associated with a number of CNS maladies, but may also provide protection to the injured CNS. Here, we will review the physiological and pathophysiological functions of IL-1β in the central nervous system with regard to synaptic plasticity. With respect to disease, emphasis will be placed on stroke, epilepsy, Parkinson's disease and Alzheimer's disease where the ultimate injurious or reparative effects of IL-1β appear to depend on time, concentration and environmental milieu.

Indexed as

IL-1InjuryInterleukin 1NeurodegenerationNeuroinflammationNeurological diseaseProtectionRepair

Identifiers

PMID26082912
PMCPMC4465544

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.